A Phase II Study of Everolimus and Sorafenib in Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Sorafenib Alone
The purpose of this research study is to:
1. Find out if sorafenib and everolimus prevent the growth of tumors that have grown when
treated with sorafenib alone
2. Find out how long one might benefit from treatment with sorafenib and everolimus
3. Find out what side effects this drug may cause
4. Measure the amount of sorafenib and everolimus in the blood and see if "markers" can be
found to help understand who might benefit from sorafenib and everolimus.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the efficacy of everolimus and sorafenib (progression free survival, objective response rate and stable disease) in patients with advanced differentiated thyroid cancer who have progressed on sorafenib alone.
Every 4 weeks
Marcia Brose, MD, PhD
Hospital of the University of Pennsylvania- Abramson Cancer Center
United States: Food and Drug Administration
|Hospital of the University of Pennsylvania||Philadelphia, Pennsylvania 19104|